Cargando…

Telomere status in chronic lymphocytic leukemia with TP53 disruption

In chronic lymphocytic leukemia (CLL), telomere dysfunction is associated with poor outcomes. TP53 is involved in cellular responses to dysfunctional telomeres, and its inactivation is the strongest adverse prognostic factor for CLL. Given the biological relationship between TP53 and telomeres, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guièze, Romain, Pages, Mélanie, Véronèse, Lauren, Combes, Patricia, Lemal, Richard, Gay-bellile, Mathilde, Chauvet, Martine, Callanan, Mary, Kwiatkowski, Fabrice, Pereira, Bruno, Vago, Philippe, Bay, Jacques-Olivier, Tournilhac, Olivier, Tchirkov, Andreï
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302966/ https://www.ncbi.nlm.nih.gov/pubmed/27486974 http://dx.doi.org/10.18632/oncotarget.10927

Ejemplares similares

ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis
por: Gay‐Bellile, Mathilde, et al.
Publicado: (2016)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
por: Gay-Bellile, Mathilde, et al.
Publicado: (2017)

Docosahexaenoic Acid Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells
por: Guièze, Romain, et al.
Publicado: (2015)

State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
por: Lemal, Richard, et al.
Publicado: (2019)

Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker
por: Faugeras, Eve, et al.
Publicado: (2022)

BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18–30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial
por: Kwiatkowski, Fabrice, et al.
Publicado: (2016)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

Lung Postmortem Autopsy Revealing Extramedullary Involvement in Multiple Myeloma Causing Acute Respiratory Distress Syndrome
por: Ravinet, Aurélie, et al.
Publicado: (2014)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

The Presence of Telomere Fusion in Sporadic Colon Cancer Independently of Disease Stage, TP53/KRAS Mutation Status, Mean Telomere Length, and Telomerase Activity
por: Tanaka, Hiromi, et al.
Publicado: (2014)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Interleukin-6 gene amplification and shortened survival in glioblastoma patients
por: Tchirkov, A, et al.
Publicado: (2007)

Lessons from TP53 mutations in breast cancers: from carcinogen fingerprints to clinical correlates
por: Hainaut, P, et al.
Publicado: (2000)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Elevated telomere dysfunction in cells containing the African-centric Pro47Ser cancer-risk variant of TP53
por: Tutton, Stephen, et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma
por: Guo, Yanan, et al.
Publicado: (2013)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

The Role of TP53 in Adaptation and Evolution
por: Voskarides, Konstantinos, et al.
Publicado: (2023)

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2021)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer
por: Kwiatkowski, Fabrice, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dpud9d7stasqdeq57vstejgbi9